The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuati ...

Phibro Animal Health Corporation’s (PAHC) focus on advancing vaccine technologies is poised to drive growth in the upcoming quarters. The company’s global growth prospects look encouraging. Yet, adverse currency fluctuations and fierce competitive impacts are concerns for Phibro’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have rallied 82.8% compared with the industry’s 9.6% growth and the S&P 500 composite's 26.7% increase.The renowned animal health and mineral nutrition compan ...

Phibro Animal Health (PAHC) has seen impressive momentum in the past year, with its shares soaring 82.8%. It has significantly outperformed the 9.6% rise of the industry and the S&P 500 Composite’s 26.7% gain.Presently carrying a Zacks Rank #3 (Hold), the diversified animal health and mineral nutrition company is benefiting from the remarkable performance of the Animal Health business. Phibro is well-positioned to pursue global growth opportunities, while the resilience of the Mineral Nutrition arm is highl ...

Core Insights - Phibro Animal Health Corporation (PAHC) is experiencing growth in its Animal Health business, driven by advancements in vaccine technologies and a rebound in Mineral Nutrition and Performance Product sectors [1][4][9] - The company's shares have significantly outperformed the industry and the S&P 500 over the past year, with a 107.9% increase compared to the industry's 20.9% and the S&P 500's 32.4% [2] - Phibro's market capitalization stands at $872 million, and it has consistently surpassed earnings estimates, achieving an average surprise of 25.47% over the last four quarters [2] Phibro's Key Tailwinds - The Animal Health business is benefiting from increased demand for efficient food production due to natural resource scarcity, with key products like Medicated Feed Additives (MFAs) and vaccines driving growth [4] - The company reported a 14% year-over-year sales growth in the Animal Health segment for the fiscal first quarter, with vaccine net sales increasing by 22% [6][8] - Phibro has expanded its vaccine manufacturing capacity, including a new facility in Brazil for autogenous vaccines targeting swine, poultry, and aquaculture [7] Recovery in Other Segments - The Mineral Nutrition business grew by 5% year-over-year, supported by increased demand for trace minerals, while Performance Products saw a 27% increase in sales [9] - Adjusted EBITDA for these segments increased by 64%, prompting the company to raise its fiscal 2025 sales guidance [9] Macroeconomic Concerns - Phibro's operations are facing challenges from macroeconomic factors such as economic sanctions, supply chain disruptions, and inflationary pressures, which could impact profitability [11] - The cost of goods sold increased by 8.1% compared to the previous year [12] Estimate Trends - The Zacks Consensus Estimate for fiscal 2025 earnings per share has increased by 2.5% to $1.61, with revenue estimates at $1.18 billion, reflecting a 15.6% rise from the previous year [13]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill this potential is challenging [1] Group 1: Company Overview - Phibro Animal Health (PAHC) is currently recommended as a growth stock by the Zacks Growth Style Score system, which evaluates a company's real growth prospects beyond traditional metrics [2] - The company has a favorable Growth Score and a top Zacks Rank, indicating strong growth potential [2] Group 2: Earnings Growth - Historical EPS growth for Phibro is 0.9%, but projected EPS growth for this year is expected to be 35.5%, significantly higher than the industry average of 15.8% [4] Group 3: Asset Utilization - Phibro's asset utilization ratio (sales-to-total-assets ratio) is 1.07, indicating that the company generates $1.07 in sales for every dollar in assets, outperforming the industry average of 0.6 [5] Group 4: Sales Growth - The company's sales are projected to grow by 15.6% this year, compared to an industry average of 0% [6] Group 5: Earnings Estimate Revisions - The current-year earnings estimates for Phibro have been revised upward, with the Zacks Consensus Estimate increasing by 2.9% over the past month, indicating a positive trend in earnings estimate revisions [7] Group 6: Overall Positioning - Phibro has achieved a Zacks Rank of 2 and a Growth Score of B, positioning it well for potential outperformance in the growth stock category [9][11]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help ...

Company Performance - Phibro Animal Health (PAHC) shares have increased by 5.2% over the past month, reaching a new 52-week high of $25.61, and have gained 120.6% since the start of the year [1] - The company reported earnings per share (EPS) of $0.35 in its last earnings report, exceeding the consensus estimate of $0.23, although it missed the revenue estimate by 6.25% [2] - For the current fiscal year, Phibro is expected to post earnings of $1.55 per share on revenues of $1.08 billion, reflecting a 31.09% change in EPS and a 6.49% change in revenues [3] Valuation Metrics - Phibro has a Value Score of A, a Growth Score of B, and a Momentum Score of D, resulting in a combined VGM Score of A [6] - The stock trades at 16.4 times the current fiscal year EPS estimates, below the peer industry average of 24.8 times, and has a PEG ratio of 0.68 [7] Zacks Rank - Phibro currently holds a Zacks Rank of 1 (Strong Buy) due to favorable earnings estimate revisions from analysts, indicating potential for further gains [8] Industry Comparison - The Medical - Products industry is performing well, ranking in the top 34% of all industries, providing a favorable environment for both Phibro and its peer, OraSure Technologies, Inc. [11]

Have you evaluated the performance of Phibro Animal Health's (PAHC) international operations for the quarter ending September 2024? Given the extensive global presence of this maker of animal health products and nutritional supplements, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financi ...

Financial Performance and Key Metrics - Consolidated net sales for Q1 2025 were $260.4 million, reflecting a 13% increase year-over-year [16] - The Animal Health segment grew 14%, Mineral Nutrition grew 5%, and Performance Products grew 27% [10][16] - Adjusted EBITDA increased by $12 million or 64% compared to the prior year [17] - GAAP net income and diluted EPS increased significantly due to higher demand and improved gross margin [16] Business Segment Performance - Animal Health segment net sales were $182.5 million, a 14% increase, driven by MFA and vaccine sales [18] - MFA and other net sales grew by 15%, while vaccine sales increased by 22% [10][18] - Mineral Nutrition net sales were $59.1 million, a 5% increase, with adjusted EBITDA of $3.8 million [20] - Performance Products segment net sales were $18.8 million, reflecting a 27% increase, with adjusted EBITDA of $2.3 million [21] Market Data and Key Metrics - The company generated $41 million of positive free cash flow for the 12 months ended September 30, 2024 [22] - Cash and cash equivalents were $90 million at the end of the quarter [22] - The gross leverage ratio was 3.9 times, and the net leverage ratio was 3.1 times at the end of Q1 [22] Company Strategy and Industry Competition - The company anticipates mid single-digit revenue growth for fiscal year 2025, excluding the Zoetis acquisition [14][30] - The Phibro Forward program is expected to enhance operating efficiencies and revenue growth in the upcoming fiscal years [11][26] - The acquisition of Zoetis' Medicated Feed Additive business is expected to significantly enhance the company's scale and market position [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued demand for products and a bright future post-acquisition [13][32] - The company expects favorable momentum to continue throughout fiscal year 2025 [14][30] - Management noted that the guidance does not include the Zoetis portfolio, which is expected to contribute approximately $200 million in revenue for the remaining eight months of fiscal year 2025 [30] Other Important Information - The company paid a quarterly dividend of $0.12 per share, totaling $4.9 million [23] - The new credit facility has an initial aggregate principal amount of $610 million, with extended maturity dates [25] Q&A Session Summary Question: What drove the healthy gross margins? - Management indicated that strong performance in the vaccine portfolio and favorable input costs contributed to the positive gross margin [34] Question: Any surprises during the acquisition process? - Management reported no significant surprises, noting optimism about the acquired portfolio [35][36] Question: Clarification on Zoetis MFA revenue and EPS guidance? - Management explained that the lower revenue estimate for the Zoetis acquisition is due to transition-related destocking and regulatory impacts [40][41] Question: Insights on the discontinued atopic dermatitis product? - Management stated that the product did not meet their target product profile, but they remain bullish on their overall pipeline [42][43] Question: Sustainability of MFA growth? - Management highlighted strong demand and favorable seasonal factors contributing to the growth in the MFA segment [44][45]